Amneal Pharmaceuticals (AMRX) EBIT (2017 - 2026)

Amneal Pharmaceuticals' EBIT history runs 10 years deep, the most recent figure standing at $141.8 million for Q1 2026.

• On a quarterly basis, EBIT rose 41.28% year-over-year to $141.8 million in Q1 2026; TTM through Mar 2026 was $435.5 million, a 20.84% increase from a year earlier, with the FY2025 full-year figure at $394.1 million, up 58.06% from the prior year.
• EBIT improved to $141.8 million in Q1 2026 per AMRX's latest filing, from $112.0 million in the prior quarter.
• Across five years, EBIT topped out at $141.8 million in Q1 2026 and bottomed at -$198.6 million in Q2 2022.
• The 5-year median for EBIT is $75.8 million (2024), against an average of $57.3 million.
• Across the five-year window, EBIT slumped 395.92% in 2022 and surged 34349.0% in 2023, its largest moves.
• Year by year, EBIT stood at $138.1 million in 2022, then tumbled by 89.72% to $14.2 million in 2023, then jumped by 434.02% to $75.8 million in 2024, then jumped by 47.81% to $112.0 million in 2025, then increased by 26.54% to $141.8 million in 2026.
• Per Business Quant, the three latest AMRX EBIT figures stand at $141.8 million (Q1 2026), $112.0 million (Q4 2025), and $70.3 million (Q3 2025).